Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

High expression of agrin is associated with tumor progression and poor prognosis in hepatocellular carcinoma

Department of Oncology,The Second Hospital of Nanjing, Nanjing University of Chinese Medicine,Nanjing, Jiangsu,210003,China

The heparan sulfate proteoglycan agrin is known to accumulate in the context of hepatocellular carcinoma (HCC). Agrin is important for neoangiogenesis in HCC tissues, and is incorporated into newly formed vasculature, but exactly how agrin contributes to the pathology of HCC remains to be fully defined. We therefore examined the clinical relevance of agrin as it pertains to HCC progression and prognosis using tissue sections from a total of 313 HCC patients. We found that agrin expression was detectable in more HCC samples (25.4% vs. 77.1%; P < 0.05) compared to normal tissue controls. Agrin expression was notably linked to tumor size (P = 0.041) and metastasis (P = 0.034). The recurrence free survival rate of agrin-positive HCC patients was considerably lower than that of agrin-negative patients (P = 0.001). We further confirmed HCC survival to be independently correlated with tumor size, metastasis, microvascular invasion and edmondson Grade via a Cox regression analysis. Upregulation of Agrin may play a crucial role in HCC progression. Together our results suggest that Agrin has the potential to be used as a prognostic indicator in predicting HCC patient outcomes.
  Figure/Table
  Supplementary
  Article Metrics

References

1. F. Bray, J. Ferlay, I. Soerjomataram, et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA-Cancer J. Clin., 68 (2018), 394–424.

2. S. F. Altekruse, K. A. McGlynn, L. A. Dickie, et al., Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008, Hepatology, 55 (2012), 476–482.

3. S. Whittaker, R. Marais and A. X. Zhu, The role of signaling pathways in the development and treatment of hepatocellular carcinoma, Oncogene, 36 (2010), 4989–5005.

4. H. Huynh, R. W. Ong, P. Y. Li, et al ., Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma, Anticancer Agents Med. Chem., 11 (2011), 560–575.

5. P. Kischel, F. Guillonneau, B. Dumont, et al ., Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells, Neoplasia, 10 (2018), 1014–1020.

6. P. Tátrai, A. Somorácz, E. Batmunkh, et al ., Agrin and CD34 immunohistochemistry for the discrimination of benign versus malignant hepatocellular lesions, Am. J. Surg. Pathol., 33 (2009), 874–885.

7. P. Tatrai, J. Dudas, E. Batmunkh, et al ., Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma, Lab Invest., 86 (2006), 1149–1160.

8. U. Winzen, G. J. Cole and W. Halfter, Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters, J. Biol. Chem., 278 (2003), 30106–30114.

9. G. Bezakova and M. A. Ruegg, New insights into the roles of agrin, Nat. Rev. Mol. Cell Biol., 4 (2003), 295–308.

10. A. Somorácz, P. Tátrai, G. Horváth, et al., Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas, Hum. Pathol., 41 (2010), 1310–1319.

11. M. Gautam, P. G. Noakes, L. Moscoso, et al., Defective neuromuscular synaptogenesis in agrin-deficient mutant mice, Cell, 85 (1996), 525.

12. E. Batmunkh, P. Tátrai, E. Szabó, et al., Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma, Hum. Pathol., 38 (2007), 1508–1515.

13. L. C. van Kempen , D. J. Ruiter , G. N. van Muijen, et al., The tumor microenvironment: a critical determinant of neoplastic evolution, Eur. J. Cell Biol., 82 (2004), 539–548.

14. A. Naba, K. R. Clauser, S. Hoersch, et al., The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices, Mol. Cell Proteom., 11 (2012): M111.014647.

15. U. Barash, V. Cohen-Kaplan, I. Dowek, et al., Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis, FEBS J., 277 (2010), 3890–3903.

16. A. D. Theocharis, S. S. kandalis, G. N. Tzanakakis, et al., Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting, FEBS J., 277 (2010), 3904–3923.

17. R. V. Iozzo and R. D. Sanderson, Proteoglycans in cancer biology, tumour microenvironment and angiogenesis, J. Cell Mol. Med., 15 (2011), 1013–1031.

18. I. J. Edwards, Proteoglycans in prostate cancer, Nat. Rev. Urol., 9 (2012), 196–206.

19. C. Mundhenke, K. Meyer, S. Drew, et al., Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas, Am. J. Pathol., 160 (2002): 185–194.

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved